Evidence map›Paper›PMID 41056574›Full record

ArticleChemMedChem2025

Coumarin-Caged Nanoparticle for Light-Driven Surface Modification.

Jan Birringer, Johannes Konrad, Stephan Melchner, Marius Remmert, Achim Goepferich

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jan BirringerDepartment of Pharmaceutical Technology, University of Regensburg, Regensburg, 93053, Bavaria, Germany.ORCID https://orcid.org/0009-0006-1847-2075
Johannes KonradDepartment of Pharmaceutical Technology, University of Regensburg, Regensburg, 93053, Bavaria, Germany.ORCID https://orcid.org/0009-0003-2261-1398
Stephan MelchnerDepartment of Pharmaceutical Technology, University of Regensburg, Regensburg, 93053, Bavaria, Germany.ORCID https://orcid.org/0009-0009-9348-1897
Marius RemmertDepartment of Pharmaceutical Technology, University of Regensburg, Regensburg, 93053, Bavaria, Germany.ORCID https://orcid.org/0009-0006-2277-4367
Achim GoepferichDepartment of Pharmaceutical Technology, University of Regensburg, Regensburg, 93053, Bavaria, Germany.ORCID https://orcid.org/0000-0002-7646-0252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photo-labile protecting groups (PPG) allow for the selective activation of an originally caged moiety by light exposure at a specific wavelength. Incorporation of PPG in nanoparticles (NPs) enables precise spatiotemporal control over NPs surface properties. Thus, physicochemical and biological properties of NPs can be modified even after administration in a biological environment. In this study, this mechanism is used to control the cell uptake of NPs. To this end, polymeric core-shell NPs are used composed of poly(D, L-lactide-co-glycolide) and a poly(ethylene glycol)-b-poly(D, L-lactide) block copolymer, modified with positively charged cell-penetrating peptide (CPP). Surface charge of CPP-NPs (+23.50 mV), measured as zetapotential, is effectively diminished by the attachment of coumarin-derived PPG to CPP (+12.50 mV), resulting in reduced cell uptake. Upon light irradiation with light-emitting diode (λ = 365 nm) the PPG is cleaved, restoring the zetapotential (+24.67 mV) and triggering an enhanced cell uptake. This opens the door to trigger the cellular uptake of NPs that are intended to transport drugs to their target cells in the future.

Indexed as

CoumarinsLightNanoparticlesCell-Penetrating PeptidesHeLa CellsHumansMolecular StructureParticle SizePolyethylene GlycolsSurface PropertiesCell-Penetrating PeptidescoumarinCoumarinsPolyethylene Glycolscell‐penetrating peptidescharge‐mediated uptakenanoparticlesstimuli‐responsivesurface chemistry

Identifiers

PMID41056574
PMCPMC12640661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.